Company intelligence / Profile preview

Elex Biotech

Portland, Oregon, United Stateselexbiotech.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Elex Biotech developed small molecule therapies targeting the RyR2 channel to address underlying causes of cardiac arrhythmias and heart failure. Their approach focused on stabilizing this calcium channel in heart muscle cells. The company advanced through preclinical stages with a stated goal of entering Phase 1 trials, but there is no public evidence that any program reached late-stage clinical development or commercialization.

Therapeutic areas: Cardiovascular
Modalities: Small moleculeNew chemical entities (NCEs)
Industry: Biotech

Beyond the preview

Go deeper on Elex Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elex Biotech.

Explore the full profile